Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia
Launched by BASILEA PHARMACEUTICA · May 12, 2006
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
Ceftobiprole medocaril is a cephalosporin antibiotic with anti-MRSA (Methicillin-Resistant Staphylococcus Aureus) activity. Ceftobiprole medocaril is not yet approved for the treatment of community-acquired pneumonia. This is a randomized, double-blind, multicenter study of ceftobiprole medocaril plus placebo versus a comparator to assess the effectiveness and safety of ceftobiprole medocaril in patients with community-acquired pneumonia. The patients will be randomized to ceftobiprole medocaril plus placebo or a comparator. Patients who meet specified criteria may be switched to an alterna...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients suffering from community-acquired pneumonia severe enough to require hospitalization
- • Female patients must be postmenopausal for at least 1 year, surgically sterile, or practicing an effective method of birth control before entry and throughout the study
- Exclusion Criteria:
- • Patients with known or suspected hypersensitivity to any related antibiotic medications
- • Treatment with any experimental drug within 30 days before enrollment
- • Prior enrollment in this study or any study with ceftobiprole medocaril
About Basilea Pharmaceutica
Basilea Pharmaceutica is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for infectious diseases and cancer. With a strong commitment to addressing unmet medical needs, Basilea focuses on pioneering research and development of novel compounds, leveraging cutting-edge science to enhance patient outcomes. The company strives to bring groundbreaking treatments to market, supported by a robust pipeline and strategic partnerships, while adhering to the highest standards of quality and regulatory compliance in its clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
Study Director
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials